Key Takeaways
- • UK biotech venture capital reached a record £2.05 ($2.76) billion in Q2 2026, part of total equity financing of £2.11 ($2.84) billion—a five-year high—according to the BioIndustry Association.
- • Isomorphic Labs' £1.6 ($2.1) billion Series B round dominated the quarter, validating UK leadership in AI-driven drug discovery and accounting for a substantial portion of venture activity.
- • Excluding the Isomorphic Labs mega-round, UK biotech companies raised £498 ($666) million in venture capital during Q2—nearly double the £279 ($373) million secured in Q2 2025, indicating broad-based sector recovery.
- • The UK captured 61% of Europe's £3.3 ($4.4) billion venture capital total in Q2, cementing its position as Europe's leading biotech investment destination.
- • Institutional capital deployment signals sustained momentum: Nest committed £1 ($1.3) billion via Schroders Capital UK Innovation LTAF for UK pension savers, while the British Business Bank invested £25 ($33) million in Alchemab—its largest direct life sciences investment to date.
Summary
UK biotech financing has reached a five-year peak in the second quarter of 2026, with total equity financing climbing to £2.11 ($2.84) billion, of which a record £2.05 ($2.76) billion came from venture capital sources, according to new data released by the BioIndustry Association. The milestone represents a significant inflection point for the sector following years of constrained funding conditions and reflects renewed institutional confidence in UK-based life sciences companies.
The quarter was heavily influenced by Isomorphic Labs' landmark £1.6 ($2.1) billion Series B financing round, which the BIA highlighted as a major validation of the UK's competitive position in AI-driven drug discovery. However, the underlying health of the sector extends well beyond this single transaction. Excluding Isomorphic Labs' mega-round, UK biotech companies secured £498 ($666) million in venture capital during Q2—representing a near doubling from the £279 ($373) million raised in the same quarter last year. This suggests broad-based recovery across the investment landscape rather than dependence on isolated mega-deals.
The UK has further solidified its European dominance, accounting for 61% of the continent's £3.3 ($4.4) billion in biotech venture capital during Q2 2026. This leadership position reflects both the country's deep scientific infrastructure and the recovery in investor appetite for UK-domiciled life sciences assets. Alongside Novartis' $1.5 billion acquisition of Myricx Bio, these transactions point to sustained M&A and venture activity in the sector.
Institutional capital flows underscore the momentum. Nest's commitment of £1 ($1.3) billion in venture capital for UK pension savers—channeled through Schroders Capital's UK Innovation Long-Term Asset Fund—represents a landmark commitment of domestic capital to high-growth scale-ups. Simultaneously, the British Business Bank has increased its deployment pace, with a £25 ($33) million investment into Alchemab representing the bank's largest direct life sciences investment to date. Chris Molloy, CEO of the BioIndustry Association, noted that "this quarter shows continued improvement in funding confidence and deal flow right across the UK biotech sector," while emphasizing the need to sustain momentum and attract additional institutional investors seeking proven sector returns.
The quarter was heavily influenced by Isomorphic Labs' landmark £1.6 ($2.1) billion Series B financing round, which the BIA highlighted as a major validation of the UK's competitive position in AI-driven drug discovery. However, the underlying health of the sector extends well beyond this single transaction. Excluding Isomorphic Labs' mega-round, UK biotech companies secured £498 ($666) million in venture capital during Q2—representing a near doubling from the £279 ($373) million raised in the same quarter last year. This suggests broad-based recovery across the investment landscape rather than dependence on isolated mega-deals.
The UK has further solidified its European dominance, accounting for 61% of the continent's £3.3 ($4.4) billion in biotech venture capital during Q2 2026. This leadership position reflects both the country's deep scientific infrastructure and the recovery in investor appetite for UK-domiciled life sciences assets. Alongside Novartis' $1.5 billion acquisition of Myricx Bio, these transactions point to sustained M&A and venture activity in the sector.
Institutional capital flows underscore the momentum. Nest's commitment of £1 ($1.3) billion in venture capital for UK pension savers—channeled through Schroders Capital's UK Innovation Long-Term Asset Fund—represents a landmark commitment of domestic capital to high-growth scale-ups. Simultaneously, the British Business Bank has increased its deployment pace, with a £25 ($33) million investment into Alchemab representing the bank's largest direct life sciences investment to date. Chris Molloy, CEO of the BioIndustry Association, noted that "this quarter shows continued improvement in funding confidence and deal flow right across the UK biotech sector," while emphasizing the need to sustain momentum and attract additional institutional investors seeking proven sector returns.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.